Logo image of 93M1.DE

MPH HEALTH CARE AG KONV (93M1.DE) Stock Fundamental Analysis

FRA:93M1 - Deutsche Boerse Ag - DE000A289V03 - Common Stock - Currency: EUR

23.7  +0.3 (+1.28%)

Fundamental Rating

3

93M1 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. While 93M1 seems to be doing ok healthwise, there are quite some concerns on its profitability. 93M1 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year 93M1 was profitable.
93M1 had a negative operating cash flow in the past year.
In multiple years 93M1 reported negative net income over the last 5 years.
In multiple years 93M1 reported negative operating cash flow during the last 5 years.
93M1.DE Yearly Net Income VS EBIT VS OCF VS FCF93M1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

The Return On Assets of 93M1 (34.76%) is better than 100.00% of its industry peers.
Looking at the Return On Equity, with a value of 36.71%, 93M1 belongs to the top of the industry, outperforming 84.00% of the companies in the same industry.
Industry RankSector Rank
ROA 34.76%
ROE 36.71%
ROIC N/A
ROA(3y)6.28%
ROA(5y)-2.15%
ROE(3y)6.75%
ROE(5y)-2.13%
ROIC(3y)N/A
ROIC(5y)N/A
93M1.DE Yearly ROA, ROE, ROIC93M1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20

1.3 Margins

With an excellent Profit Margin value of 470375.20%, 93M1 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
93M1's Profit Margin has declined in the last couple of years.
93M1 does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 470375.2%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-3.05%
GM growth 3YN/A
GM growth 5YN/A
93M1.DE Yearly Profit, Operating, Gross Margins93M1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 100K -100K

More info and screens

5

2. Health

2.1 Basic Checks

93M1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 93M1 has about the same amount of shares outstanding.
The number of shares outstanding for 93M1 remains at a similar level compared to 5 years ago.
Compared to 1 year ago, 93M1 has an improved debt to assets ratio.
93M1.DE Yearly Shares Outstanding93M1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
93M1.DE Yearly Total Debt VS Total Assets93M1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 4.61 indicates that 93M1 is not in any danger for bankruptcy at the moment.
93M1 has a better Altman-Z score (4.61) than 78.00% of its industry peers.
93M1 has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.03, 93M1 belongs to the top of the industry, outperforming 86.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 4.61
ROIC/WACCN/A
WACC6.9%
93M1.DE Yearly LT Debt VS Equity VS FCF93M1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M 250M

2.3 Liquidity

93M1 has a Current Ratio of 1.34. This is a normal value and indicates that 93M1 is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.34, 93M1 perfoms like the industry average, outperforming 44.00% of the companies in the same industry.
93M1 has a Quick Ratio of 1.34. This is a normal value and indicates that 93M1 is financially healthy and should not expect problems in meeting its short term obligations.
93M1 has a better Quick ratio (1.34) than 72.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.34
93M1.DE Yearly Current Assets VS Current Liabilites93M1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

93M1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 140.38%, which is quite impressive.
The Earnings Per Share has been decreasing by -4.41% on average over the past years.
93M1 shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.73%.
The Revenue has been decreasing by -1.41% on average over the past years.
EPS 1Y (TTM)140.38%
EPS 3YN/A
EPS 5Y-4.41%
EPS Q2Q%583.72%
Revenue 1Y (TTM)-25.73%
Revenue growth 3Y-18.75%
Revenue growth 5Y-1.41%
Sales Q2Q%-2.99%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
93M1.DE Yearly Revenue VS Estimates93M1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
93M1.DE Yearly EPS VS Estimates93M1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.85, which indicates a rather cheap valuation of 93M1.
Based on the Price/Earnings ratio, 93M1 is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 28.79, 93M1 is valued rather cheaply.
Industry RankSector Rank
PE 0.85
Fwd PE N/A
93M1.DE Price Earnings VS Forward Price Earnings93M1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
93M1.DE Per share data93M1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

6

5. Dividend

5.1 Amount

93M1 has a Yearly Dividend Yield of 5.13%, which is a nice return.
93M1's Dividend Yield is rather good when compared to the industry average which is at 3.15. 93M1 pays more dividend than 86.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.51, 93M1 pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.13%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
93M1.DE Yearly Dividends per share93M1.DE Yearly Dividends per shareYearly Dividends per share 2024 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
93M1.DE Yearly Income VS Free CF VS Dividend93M1.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

More info and screens

MPH HEALTH CARE AG KONV

FRA:93M1 (4/25/2025, 7:00:00 PM)

23.7

+0.3 (+1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-21 2024-11-21
Earnings (Next)06-09 2025-06-09
Inst Owners0.87%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap101.44M
Analysts85.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.13%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.85
Fwd PE N/A
P/S 3993.54
P/FCF N/A
P/OCF N/A
P/B 0.31
P/tB 0.31
EV/EBITDA N/A
EPS(TTM)27.91
EY117.76%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.61
FCFYN/A
OCF(TTM)-5.6
OCFYN/A
SpS0.01
BVpS76.05
TBVpS76.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 34.76%
ROE 36.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 470375.2%
GM N/A
FCFM N/A
ROA(3y)6.28%
ROA(5y)-2.15%
ROE(3y)6.75%
ROE(5y)-2.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-3.05%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.34
Quick Ratio 1.34
Altman-Z 4.61
F-Score5
WACC6.9%
ROIC/WACCN/A
Cap/Depr(3y)19.42%
Cap/Depr(5y)110.58%
Cap/Sales(3y)13.26%
Cap/Sales(5y)34.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)140.38%
EPS 3YN/A
EPS 5Y-4.41%
EPS Q2Q%583.72%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-25.73%
Revenue growth 3Y-18.75%
Revenue growth 5Y-1.41%
Sales Q2Q%-2.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-421.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-421.04%
OCF growth 3YN/A
OCF growth 5YN/A